Articles tagged with Heart Failure
A recent study has found that post-traumatic stress disorder (PTSD) is associated with a nearly 50% greater risk of developing heart failure among veterans. The research adds to growing evidence linking PTSD and heart disease, suggesting a potential causal relationship between the two conditions.
A collaborative study by 11 major US healthcare providers found that psychiatric comorbidities increase 30-day readmissions for heart failure, AMI, and pneumonia. The study suggests that depression, anxiety, and substance abuse may be key targets for screening efforts to reduce readmission rates.
Scientists have identified PDE-9 as the long-sought culprit in heart failure by analyzing lab animals and human heart cells. The enzyme interferes with the body's natural 'braking' system, leading to progressive weakening and stiffening of the heart muscle.
A comprehensive study of over 95,000 patients found that glucose-lowering therapies prescribed to diabetes patients may pose an increased risk for the development of heart failure. The study showed a 14% overall increased risk of heart failure with intensive blood sugar-lowering drugs or strategies.
A new study finds that carotid baroreflex activation therapy (BAT) improves NYHA Class, quality of life scores and exercise capacity in symptomatic advanced heart failure patients receiving optimum drug therapy. BAT was safely implanted with few complications and no adverse effects.
A study by the American College of Cardiology found that catheter ablation significantly reduces atrial fibrillation symptoms and hospitalization rates compared to Amiodarone in heart failure patients. Patients who underwent catheter ablation had a higher rate of freedom from atrial fibrillation after two years, with 71% being symptom-...
The study found that Bendavia did not prevent irreversible injury to the heart but showed a trend towards improved heart pumping function. The drug is well-tolerated but lacks significant benefits in reducing scarring from angioplasty after a heart attack.
A new study found that monitoring calcitriol levels can predict cardiovascular death in chronic heart failure patients. The ratio of calcitriol to parathyroid hormone was also strongly related to heart failure severity and mortality.
A study published in Cell Reports identified RBFox2 as a critical protein in the progression from weakened heart muscle to heart failure. The researchers found that reduced RBFox2 expression coincides with weakening of the heart muscle, suggesting a causal role in heart failure.
A study has quantified the average number of heart failure-free years a person gains by not developing risk factors such as obesity, hypertension, and diabetes by age 45. The results show that individuals with all three risk factors are diagnosed with heart failure an average of 11 to 13 years earlier than those without any risk factors.
Researchers found that paroxetine, a commonly prescribed antidepressant, restored heart function in mice with heart failure by inhibiting the GRK2 enzyme. The study's findings suggest that physicians may consider prescribing paroxetine to heart failure patients with clinical depression to improve their heart function.
A urine test can predict the risk of kidney injury in heart failure patients, allowing clinicians to identify those at high risk and take preventive measures. The study found that urinary angiotensinogen levels can accurately predict acute kidney injury and patient rehospitalization or death within one year.
Research suggests that heart failure patients who struggle with daily activities are at a higher risk of hospitalization and early death. The study found that older women, unmarried individuals, and those with chronic conditions such as obesity, dementia, anemia, and diabetes were more likely to experience these negative outcomes.
A new Yale University study found that patients are at risk of rehospitalization or death within a year after being discharged from the hospital, with risks remaining high even after several months. The researchers tracked 3 million Medicare patients and discovered specific risks vary by discharge diagnosis and outcomes over time.
Researchers have developed a technology that mimics the cellular environment to restore organ function and promote tissue regeneration. The bioengineered miniature structures can release biologically active peptides to protect and repair damaged heart muscle cells.
A large Canadian Medical Association Journal study found that combining trimethoprim-sulfamethoxazole with spironolactone more than doubles the risk of sudden death in older patients. The study suggests that physicians should consider alternative antibiotics for patients on spironolactone to reduce this risk.
A study by Nova Southeastern University researchers found that Valsartan and Candesartan are more effective in preventing aldosterone production, which can lead to heart failure. This discovery may help cardiologists choose the best ARB drug for treating heart failure patients.
A Yale-led study found that 11% of hospitalized heart failure patients received intravenous fluids in addition to diuretics. Patients given both therapies were more likely to suffer adverse consequences, such as higher rates of critical care admission and even death.
A study assessed self-care barriers in acute heart failure patients returning to the ER. Common barriers include co-morbidities, physical disability, and knowledge about disease. Addressing these social determinants can improve patient outcomes and reduce readmissions.
A study by UT Southwestern Medical Center investigators found that patients with heart failure who used left ventricular assist devices (LVADs) for six months or longer showed significant regeneration of heart muscle. Oxidative damage to a cell-regulator mechanism was prevented, leading to an increase in cardiomyocyte proliferation.
A large study of nearly 15,000 men and women found that moderate alcohol consumption is associated with a lower risk of heart failure. Men who consumed up to seven drinks a week had a 20% reduced risk, while women had a 16% reduced risk compared to abstainers.
Research from Yale University finds that timely, well-communicated discharge summaries can lower hospital readmission rates among heart failure patients. The studies analyzed data from Telemonitoring to Improve Heart Failure Outcomes and found that quality of discharge summaries was associated with readmission risk.
A new study reveals that a genetic mutation in the MYBPC3 gene causes cardiac dysfunction and is responsible for up to 8% of deaths among South Asians. The mutation affects the protein that controls heart muscle contractions, leading to toxic effects on the cell.
Patients with low illness acceptance have lower energy, more severe pain, and negative emotional reactions, leading to social isolation. Acceptance of illness is crucial for effective treatment and improved daily functioning.
Researchers found that blood sugar levels above 6.1 mmol/L increase the risk of early death, further hospitalizations, and diabetes in heart failure patients, even if they have normal blood sugar levels on arrival.
A new study published in the Journal of the American College of Cardiology found that obese heart failure patients have better survival rates than normal-weight patients. Over a 10-year follow-up period, 38% of obese and 45% of overweight patients died compared to 51% of normal weight patients.
During the annual hajj pilgrimage, scientists detected high levels of air pollutants, including carbon monoxide and benzene, in Mecca. The exposure to these chemicals increases the risk of heart failure, headaches, and other serious health issues, highlighting the need for improved regulations and reduced emissions.
A study found that obesity causes subclinical heart muscle injury and increases the risk for heart failure, even in people without overt heart disease. Obesity was independently associated with increased troponin levels, a marker of heart damage.
A new study led by University of Pennsylvania researchers found that black and white heart failure patients have similar rates of atrial fibrillation, contradicting previous studies. The study suggests that physicians should monitor all heart failure patients for atrial fibrillation regardless of race.
A Swedish registry study suggests that beta blockers can improve survival in patients with HFPEF, which affects women more often than men and is characterized by an impaired ability to relax and fill with blood. The treatment difference persisted even after adjusting for various factors.
The overall heart disease death rate decreased by 3.8% and coronary artery disease death rate by 5.1% between 2000-2010, but some subtypes showed increases in mortality rates, including hypertensive heart disease (HHD) and arrhythmia.
A study found that beta-blockers are associated with lower all-cause mortality in heart failure patients with preserved ejection fraction, but no significant effect on combined all-cause mortality or heart failure hospitalization. The study used data from the Swedish Heart Failure Registry and included over 41,000 patients.
A new program called Family SWAP uses an electronic monitoring device to help heart failure patients and their caregivers adapt to a low-salt diet. The study found that participants noticed a significant change in their ability to taste salt, while caregivers reported no increased burden.
A new study by Dr. Ankur Kalra identifies a significant risk factor for heart failure progression in Hypertrophic Cardiomyopathy patients using Doppler Tissue Imaging. The finding could lead to more aggressive management and closer monitoring of high-risk patients.
Researchers at MIT developed an algorithm that can accurately determine whether a patient is suffering from emphysema or heart failure based on carbon dioxide readings in their breath. The algorithm achieved an area under the curve of 0.98, outperforming traditional diagnostic methods.
A clinical study found that high levels of TMAO, a chemical byproduct of intestinal bacteria digestion, are linked to an increased risk of heart failure and poor long-term prognosis. Patients with low TMAO levels had a lower mortality rate despite advanced heart failure symptoms.
A new implantable device has shown promising results in slowing and reversing heart failure in patients with severe cases. The C-Pulse system, a cuff that wraps around the aorta, improves NYHA functional class and quality of life scores.
Researchers at the University of Maryland School of Medicine have identified a new pathway that connects the brain to increased blood pressure, involving the unusual steroid ouabain. This discovery offers potential new approaches for treating high blood pressure and heart failure.
Researchers found that high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide levels strongly predict heart failure in individuals with mild to severe kidney disease. These biomarkers may indicate subclinical cardiovascular changes, contributing to the development of heart failure.
Researchers found that oleate, a common dietary fat, restored proper metabolism of fuel in an animal model of heart failure. This improvement enabled the heart muscle to access energy more efficiently and reduced toxic fatty byproducts.
Researchers at the University of Alberta have explained how a key protein in the heart changes in heart failure, shedding light on the molecular mechanisms behind this complex condition. By studying troponin I, they discovered that increased calcium sensitivity actually helps trigger contraction, despite slower relaxation.
Researchers have discovered a six-fold higher risk of developing heart failure among people with diabetes who appear healthy. A highly sensitive test found elevated troponin levels indicating microscopic heart muscle damage, unrelated to high cholesterol.
Temple University researchers discovered a promising new target for treating end-stage heart failure by blocking the vasopressin type 1A receptor, which interferes with the heart's ability to receive important signals. The finding could lead to more effective therapies and improve symptoms in patients with heart failure.
A recent study published in Journal of the American Society of Nephrology found that CKD patients who experience multiple heart failure hospitalizations are at a higher risk of developing kidney failure. The study's findings suggest that coordinated care between specialists is crucial in managing these patients.
Researchers compared ultrathin strut sirolimus-eluting stents to thin strut everolimus-eluting stents, finding similar target lesion failure risks. A meta-analysis of β blocker therapy in heart failure with atrial fibrillation found no significant benefit over rate-control medications.
The study found that clinical variables explained over 80% of non-adherence to heart failure guidelines, with health structure characteristics playing a significant role. Countries with incentivized programs and high numbers of general practitioners per population had higher adherence rates.
Heart failure affects millions worldwide, yet awareness is low among politicians, healthcare professionals, and the public. Many cases are preventable and treatable, improving quality of life and survival.
The ANTHEM-HF study shows significant improvement in left ventricular ejection fraction and 6-minute walk test distance with both left and right vagus nerve stimulation. However, the improvement was significantly less with left-sided VNS compared to right-sided VNS.
The RELAX-AHF trial found that serelaxin reduced the occurrence of worsening heart failure within the first 5 days of admission by 12.2% compared to 6.7% in placebo groups, resulting in a significant reduction in repeated episodes of worsening heart failure and hospitalization length.
A new study by SEPTAL-CRT found that mid-septal RV lead placement in heart failure patients undergoing CRT results in similar outcomes compared to the conventional apical position. The study showed no differences in clinical outcome or implantation success rates between the two groups.
The MORE-CRT study demonstrates the safety and efficiency of quadripolar lead technology in managing common pacing complications during cardiac resynchronisation therapy. At six months, patients with quadripolar leads showed a significant reduction in intra- and post-operative LV lead-related complications compared to bipolar lead cont...
The PARADIGM-HF trial found LCZ696 to be superior to enalapril in reducing cardiovascular mortality and hospitalization for heart failure. The study showed a 20% reduction in death from cardiovascular causes and a 21% reduction in hospitalization for heart failure.
A study found that intravenous iron supplementation improved functional capacity and quality of life in heart failure patients with iron deficiency, reducing hospital admissions for worsening heart failure. The treatment also showed benefits in measures of functional status and quality of life.
The NEART-HF trial found no clinical benefit of vagus nerve stimulation for heart failure patients, despite robust pre-clinical data suggesting a potential therapeutic effect. However, the treatment did show improvements in quality of life and functional classification.
The European Society of Cardiology has launched newregistries for cardiac oncology and ACS, aiming to monitor treatment practices and outcomes. The registries will provide robust data on cardiovascular disease burden and treatment in Europe.
Heart failure affects millions worldwide, resulting in poor survival rates and a huge burden on healthcare systems. The Heart Failure Association calls for improved awareness and policy initiatives to prevent the disease and promote equity of care. Implementation could reduce deaths and improve quality of life globally.
A team at the University of Leeds used a standard TENS machine to apply electrical pulses to the tragus, reducing nervous signals that can drive failing hearts too hard. The stimulation changed the influence of the nervous system on the heart by increasing heart rate variability and suppressing sympathetic nervous system activity.
A study by Massachusetts General Hospital finds that patients with frequent ED visits for acute heart failure syndrome account for disproportionate costs and service utilization. The research highlights the need for better outpatient care to prevent repeat ED visits and reduce hospitalizations.
A new UCLA-led research study has found that racial and ethnic minorities who receive implantable devices to treat heart failure derive the same substantial survival benefit as white patients. The study, involving over 15,000 patients, monitored two years of data from a registry to improve heart failure therapies in outpatient settings.
A systematic review found that heart failure is a substantial health burden in low- and middle-income countries, with significant variation in presentation, causes, and management across different regions. The study also highlights the need for more research attention to address this public health issue.